Tamtam Try Tamtam free
Fortrea logo

Fortrea account plan

Clinical development solutions

At a glance

Fortrea is a global contract research organization spun off from Labcorp, with $2,723.4 million of 2025 revenue and about 14,000 employees in 100 countries.

Fortrea is a contract research organization (CRO) providing phase I-IV clinical trial management, clinical pharmacology and consulting services to pharmaceutical, biotechnology and medical device customers, through Full Service, FSP and Hybrid models. It was spun off from Labcorp on June 30, 2023, trades on Nasdaq as FTRE and is headquartered in Durham, North Carolina, with about 14,000 employees working in approximately 100 countries. FY2025 revenues were $2,723.4 million (+1.0%), with a net loss of $(986.2) million driven by $797.9 million of goodwill impairment; backlog was $7.7 billion at December 31, 2025. Anshul Thakral is President and CEO.

Business units

Strategic priorities

Return to growth through the 3Rs
The commercial strategy is "reach, relevance and repeat": Fortrea has been invited into large-pharma outsourcing refreshes it had not been part of before and won one, expected to convert into awards in 2028; biotech bookings grew almost double digits in 2026.
Mid-teens adjusted EBITDA margin
Management targets mid-teens margins in the next 3-5 years; the Q3 2026 adjusted EBITDA margin was 8.4%, up 120 basis points year on year.
Grow clinical pharmacology
The mix strategy is more clinical pharmacology, more FSO and less low-margin FSP, with a 300-bed Texas network and an in-house Austin bioanalytical lab added in October 2026.
Fortrea Intelligent Technology
FIT, launched in 2026, is an intelligence layer on the Xcellerate platform built module by module; the CRA mobile app is deployed in more than 49 countries and more than 95% of colleagues use AI weekly.
China-linked biotech demand
A new China leader was appointed in summer 2026 to grow with China-headquartered biotechs and multinationals running trials in China.

Latest results

In Q3 2026 Fortrea's revenues were $691.5 million, down 1.4% from $701.3 million, as lower clinical development pass-through costs and lower FSP demand offset growth in clinical pharmacology. GAAP net income was $0.6 million against a net loss of $(15.9) million, and adjusted EBITDA rose to $58.0 million from $50.7 million. Net business awards were $773 million for a book-to-bill of 1.12x; after a contract review, backlog was cut by $558 million to $7,316 million. FY2026 guidance was narrowed with higher midpoints: revenues of $2,665 million to $2,690 million and adjusted EBITDA of $210 million to $218 million.

Investments and deals

Worldwide Clinical Trials Early Phase Services
Acquired on October 19, 2026 for about $45.0 million, adding a 200-bed San Antonio clinic and an Austin bioanalytical laboratory; it is expected to be EBITDA-profitable in 2027.
Debt reduction
Fortrea repurchased $75.7 million of its 7.50% senior secured notes in Q4 2025; net leverage was 3.9x at Q3 2026, 1.4 turns lower in 12 months.
Cost-savings programme
The 2026 programme targets $70-80 million gross and $40-50 million net savings; restructuring charges were $44.1 million in 2025.
Enabling Services divestment
Fortrea sold its Enabling Services Segment (Fortrea Patient Access and Endpoint Clinical) for an adjusted price of $340.0 million, fully received in 2025.

Challenges and risks

Customer concentration
The largest customer was 17.6% of Q3 2026 revenue and the top 10 customers 53.5%; in 2025 one customer was approximately 18.1% of revenue.
Revenue decline and backlog quality
Nine-month 2026 revenues fell 2.7% to $2,006.2 million, and backlog was reduced by $558 million to reflect estimated scope and study delivery changes, including inactive trials.
FSP pricing pressure
FSP is very sticky but fairly low margin, and the CEO points to irrational pricing behavior by some larger players.
Leverage and legacy losses
Long-term debt was $1,048.0 million at end-2025 after a $(986.2) million net loss; a shareholder class action was filed in June 2025.
Biotech funding and R&D budgets
Risks include delayed or cancelled awards, biotech funding swings and R&D budget cuts, along with changes in U.S. policy and tariffs.

What leadership says

“Our sustained bookings momentum is building a foundation for growth.”

Anshul Thakral, President and CEO · Q3 2026 results press release, October 29, 2026

“our goal in AI is not automation for the sake of automation. It is to create a force multiplier for our people and our clients.”

Anshul Thakral, President and CEO · Q3 2026 earnings call, October 29, 2026

“new management team, new strategy, flipping the chapter. It's not about spend, it's not about rightsizing, it's about growth.”

Anshul Thakral, President and CEO · Baird 2026 Global Healthcare Conference, September 15, 2026

“So this is really about adding capabilities, not just capacity.”

Anshul Thakral, President and CEO · Q3 2026 earnings call, October 29, 2026

Where a supplier can help

Clinical pharmacology integration
Tied to the Worldwide Clinical Trials acquisition and clinical pharmacology growth: lab equipment, LIMS, clinic operations and staffing for the San Antonio unit and the Austin bioanalytical lab.
AI and clinical data platforms
Tied to Fortrea Intelligent Technology: AI, analytics and workflow tools that plug into the Xcellerate data lake and the CRA mobile app, and integration with large pharma clients' own agentic solutions.
Efficiency in support functions
Tied to the cost-savings programme and the mid-teens margin target: outsourced support services and enterprise applications that let Fortrea scale without adding back capacity.
Site activation and patient enrolment
Tied to the operational priority on project management, site activation, enrolment and predictability: site selection, recruitment and trial technology vendors.
Biotech and China market access
Tied to biotech booking growth and the new China leader: partners that help reach U.S. and Chinese biotechs taking assets to the U.S. and Europe.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Fortrea?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Fortrea

What does Fortrea do?

Fortrea is a contract research organization running phase I-IV clinical trials, clinical pharmacology studies and consulting for pharmaceutical, biotechnology and medical device companies, through full service, FSP and hybrid models.

What is Fortrea's revenue?

Fortrea's FY2025 revenues were $2,723.4 million, up 1.0%. For 2026 it guides to revenues of $2,665 million to $2,690 million.

How many employees does Fortrea have?

Fortrea had about 14,300 employees at the end of 2025 and now cites about 14,000 employees in approximately 100 countries.

What is Fortrea's strategy?

Fortrea's return-to-growth strategy rests on commercial, operational and financial excellence: winning more large pharma and biotech work, growing clinical pharmacology, building AI into Fortrea Intelligent Technology and reaching mid-teens adjusted EBITDA margins.

Who leads Fortrea?

Anshul Thakral is President and CEO, and Jason Knoblauch is Chief Financial Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)